Etripamil Nasal Spray in Patients With Paroxysmal Supraventricular Tachycardia

Completed · Phase 3

Conditions studied: Paroxysmal Supraventricular Tachycardia

In brief

This Open Label Extension study will enable eligible patients with Paroxysmal Supraventricular Tachycardia (PSVT) who have previously participated in a Milestone Pharmaceuticals clinical trial of etripamil NS for PSVT, to access continued treatment with etripamil NS, Patients who experienced any significant safety issues during participation period in a previous clinical trial of etripamil NS, as per Investigator's assessment , are excluded. This study will be conducted by Investigators who previously participated in a Milestone Pharmaceuticals clinical trial and are trained on the use of etripamil NS.

Key facts

Study ID

NCT04952610

Run by

Milestone Pharmaceuticals Inc.

People needed

130

Starts

2021-12-13

Expected to finish

2026-04-10

Last updated by the study team

2026-05-15

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• A patient will be eligible for study participation if they meet all of the following criteria:
• Has participated in a Milestone Pharmaceuticals Inc. clinical research trial of etripamil NS for the treatment of PSVT (NODE-301 Part1, RAPID (NODE-301 Part 2), NODE-302, or NODE-303.
• Has signed the MSP-2017-1278 written informed consent;
• Women of childbearing potential who are sexually active with a male partner who is not surgically sterile (i.e., vasectomy) must be willing to use at least 1 form of highly effective contraception from the time of signed informed consent until 7 days after the last administration of etripamil NS and must be willing to discontinue from the study should they become or plan to become pregnant.
• The following categories define females who are not considered to be of childbearing potential:
• Postmenopausal females, defined as having amenorrhea for at least 12 months without an alternative medical cause; or
• Premenopausal females with 1 of the following:
• Documented hysterectomy; or
• Documented bilateral salpingectomy; or
• Documented bilateral oophorectomy; or
• All females who do not meet at least one of the above criteria are considered to be of childbearing potential
• Willing and able to comply with Investigator instructions on etripamil NS use and study requirements.

You may not qualify if…

• A patient will be excluded from the study if they meet any of the following criteria:
• History of allergic reaction to verapamil, etripamil, or any of the investigational medical components;
• Current chronic therapy with digoxin, or any Class I or III antiarrhythmic drug. Patients may be eligible if these drugs are stopped at least five half-lives before enrollment. The only exception is oral amiodarone which must be stopped 30 days before enrollment;
• History of ventricular pre-excitation, e.g., delta waves, Wolff-Parkinson-White syndrome;
• History of a second- or third-degree atrioventricular block;
• History of sick sinus syndrome and marked bradycardia (≤40 beats/minute);
• History or evidence of severe ventricular arrhythmia (e.g. torsades de points, ventricular fibrillation, or sustained ventricular tachycardia)
• Symptoms of congestive heart failure New York Heart Association Class II to IV;
• Significant physical or psychiatric condition including alcoholism or drug abuse, which, in the opinion of the Investigator, could jeopardize the safety of the patient, or impede the patient's capacity to follow the study requirements;
• Syncope due to an arrhythmic etiology or unexplained syncope during or after participation in an etripamil clinical research trial;
• Is pregnant, breastfeeding, or is planning to become pregnant during the study;
• History of acute coronary syndrome (without successful revascularization) or stroke within 6 months of enrollment;
• Evidence of symptoms of hypotension within 24 hours following previous administration of etripamil, per Investigator's opinion.
• Has experienced a significant safety issue related to study drug administration during participation in a previous etripamil study for PSVT, per the Investigator's opinion.

Where it is running

• Site # 0160 — Little Rock, Arkansas, United States
• Site # 1023 — Vista, California, United States
• Site # 1083 — West Hills, California, United States
• Site # 0102 — Atlanta, Georgia, United States
• Site # 0137 — Macon, Georgia, United States
• Site # 1115 — Coeur d'Alene, Idaho, United States
• Site # 0149 — Fort Wayne, Indiana, United States
• Site # 1025 — West Des Moines, Iowa, United States
• Site # 1007 — Salisbury, Maryland, United States
• Site # 0166 — Lansing, Michigan, United States
• Site # 0114 — New York, New York, United States
• Site # 1024 — Canton, Ohio, United States
• Site # 0110 — Toledo, Ohio, United States
• Site # 1123 — Corvallis, Oregon, United States
• Site # 0105 — Yardley, Pennsylvania, United States
• Site # 0122 — Rapid City, South Dakota, United States
• Site # 1047 — Austin, Texas, United States
• Site # 0213 — Victoria, British Columbia, Canada
• Site # 0210 — Halifax, Nova Scotia, Canada
• Site # 2006 — Oshawa, Ontario, Canada
• Site # 0204 — Toronto, Ontario, Canada
• Site # 0203 — Montreal, Quebec, Canada
• Site # 0205 — Montreal, Quebec, Canada

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.